Skip to content
No picture yet

Synjardy 850 mg / 12.5 mg – DIN 02456613

Synjardy is Metformin Hydrochloride and Empagliflozin 850 mg / 12.5 mg (tablet), sold in Canada. It is used for type 2 diabetes. It is supplied by Boehringer Ingelheim (Canada) Ltd Ltee. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.

Sold in Canada

Metformin Hydrochloride and Empagliflozin 850 mg / 12.5 mg

Brand
Synjardy
Strength
Metformin Hydrochloride 850 mg / Empagliflozin 12.5 mg
Used for
Type 2 diabetes
Form
Tablet
Manufacturer
Boehringer Ingelheim (Canada) Ltd Ltee
Drug class
Diabetes medicine (SGLT2 inhibitor)
Sold in
Canada
DIN
02456613

Source: Health Canada's Drug Product Database. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Empagliflozin and Metformin pills and guides

What is Empagliflozin and Metformin used for?

Empagliflozin and Metformin is used for type 2 diabetes.

Medicine type
Diabetes medicine (SGLT2 inhibitor); diabetes medicine (biguanide)
Official uses from the US prescribing label

SYNJARDY

SYNJARDY is a combination of empagliflozin and metformin hydrochloride (HCl) immediate-release indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.

SYNJARDY XR

SYNJARDY XR is a combination of empagliflozin and metformin HCl extended-release indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Empagliflozin

Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of:

  • Cardiovascular (CV) death in adults with established CV disease.
  • CV death and hospitalization for heart failure in adults with heart failure.
  • Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression.

Limitations of Use

  • SYNJARDY and SYNJARDY XR are not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients.
  • Because of the metformin HCl component, the use of SYNJARDY or SYNJARDY XR is limited to patients with type 2 diabetes mellitus for all indications.
  • Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Empagliflozin is not expected to be effective in these populations.

From the FDA-approved label on DailyMed (published Aug 27, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your medicine? Check the box

  • The box or bottle shows DIN 02456613.
  • It names Synjardy, Metformin Hydrochloride and Empagliflozin 850 mg / 12.5 mg.
  • A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.

Sold in Canada as Synjardy by Boehringer Ingelheim (Canada) Ltd Ltee.

In Canada: prescription only.

Ingredients

Active: Metformin Hydrochloride, Empagliflozin

Other Empagliflozin and Metformin pills